glp-1 agonist cardiovascular outcomes Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog Cardiovascular outcomes of glucagon-like peptide-1

K., Osler, M., Jrgensen, M

2 Conclusions GLP-1 RAs are multisystemic interventions capable of simultaneously addressing both physiological and some psychological barriers to weight loss

BenjafieldAVAyasNTEastwoodPRHeinzerRIpMSMMorrellMJet al

Caruso I, Cignarelli A, Giorgino F

Policy decisions on the reimbursement of tirzepatide in individual countries should be based on health technology assessments integrating long-term efficacy and safety clinical data with country-specific cost-utility analyses comparing tirzepatide with other glucose-lowering medications used in clinical practice

In most studies, the adverse events did not lead to treatment discontinuation ( An intensive discussion on the pancreatic safety of incretin-based therapies initiated by publications of a single group have led to a thorough evaluation of non-clinical and clinical data by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) ( Regarding skin lesions, bullous pemphigoid, a rare autoimmune skin disease, was found to be associated with the use of DPP-4 inhibitors in a retrospective analysis of more than 9,000 patients treated in Japan during the years 20092017